Skip to main content

Research Repository

Advanced Search

Professor Adrian Brunt's Outputs (45)

Breast Cancer Management Guidelines During COVID-19 Pandemic (2020)
Journal Article
Gowda S, M., Katherine Kabeer, K., Jafferbhoy, S., Marla, S., Soumian, S., Misra, V., Narayanan, S., & Brunt, A. M. (2020). Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82, 251-258. https://doi.org/10.1007/s12262-020-02466-7

The coronavirus disease (COVID-19) pandemic in 2020 has brought about complex challenges in healthcare delivery. With the new rules of lockdown and social distancing and with resources diverted to the management of COVID-19, there are difficulties in... Read More about Breast Cancer Management Guidelines During COVID-19 Pandemic.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., Chan, C., Churn, M., Cleator, S., Coles, P. C. E., Goodman, A., Harnett, A., Hopwood, P., Kirby, A. M., Kirwan, C. C., Morris, C., Nabi, Z., Sawyer, E., Somaiah, N., Stones, L., …Management Group, F.-F. T. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395(10237), 1613 - 1626. https://doi.org/10.1016/S0140-6736%2820%2930932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri... Read More about Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic (2020)
Journal Article
Coles, C. E., Aristei, C., Bliss, J., Boersma, L., Brunt, A. M., Chatterjee, S., Hanna, G., Jagsi, R., Person, O. K., Kirby, A., Mjaaland, I., Meattini, I., Luis, A. M., Marta, G. N., Offersen, B., Poortmans, P., & Rivera, S. (2020). International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology, 32(5), 279-281. https://doi.org/10.1016/j.clon.2020.03.006

'No abstract'

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial (2020)
Journal Article
King, M. T., Link, E. K., Whelan, T. J., Olivotto, I. A., Kunkler, I., Westenberg, A. H., Gruber, G., Schofield, P., Chua, B. H., Chua, B. H., Phillips, C., Bryant, G., Westenberg, H., Purohit, O. P.-K., Ahern, V., Graham, P., Akra, M., McArdle, O., O'Brien, P., Ludbrook, J., …Lavery, B. (2020). Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncology, 21(5), 685-698. https://doi.org/10.1016/s1470-2045%2820%2930085-1

Background
BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and w... Read More about Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (2019)
Journal Article
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Murray Brunt, A., Nemsadze, G., D. Baird, R., Hee Park, Y., S. Hall, P., Perren, T., C. Stein, R., Mangel, L., Ferrero, J.-M., Phillips, M., Conibear, J., Cortes, J., Foxley, A., C. de Bruin, E., McEwen, R., Stetson, D., …C. Turner, N. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5), 423 - 433. https://doi.org/10.1200/JCO.19.00368

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been assoc... Read More about Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial (2019)
Journal Article
Fernando, I. N., Bowden, S. J., Herring, K., Brookes, C. L., Ahmed, I., Marshall, A., Grieve, R., Churn f, M., Spooner, D., Latief, T. N., Agrawal, R. K., Brunt, A. M., Stevens, A., Goodman, A., Canney, P., Bishop, J., Ritchie, D., Dunn, J., Poole, C. J., & Rea, D. W. (2020). Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142, 52-61. https://doi.org/10.1016/j.radonc.2019.10.014

BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, ph... Read More about Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer (2019)
Journal Article
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A. M., Kuemmel, S., Ruiz, I., Perelló, A., Brown, A. K., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., …Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5(11), 1556 - 1556. https://doi.org/10.1001/jamaoncol.2019.2526

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating... Read More about Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial (2019)
Journal Article
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., Sergii, G., Petrakova, K., & Peoples, G. E. (2019). Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 25(14), 4248-4254. https://doi.org/10.1158/1078-0432.ccr-18-2867

16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) (2019)
Journal Article
Winters, Z., Roberts, N., McCartan, N., Potyka, I., Brunt, M., Maxwell, A., Greenwood, R., Ingram, J., Kandiyali, R., Schmid, P., & Williams, N. (2019). 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654). EJSO - European Journal of Surgical Oncology, 45(5), 881. https://doi.org/10.1016/j.ejso.2019.01.202

Background: Oncological safety of treating multiple ipsilateral breast cancers (MIBC) using therapeutic mammoplasty (TM) compared to mastectomy remains uncertain. A National Institute for Health Research (NIHR) - funded MIAMI feasibility phase random... Read More about 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654).

Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK (2019)
Journal Article
Brunt. (2019). Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK. Annals of Surgical Oncology, 58 - 60

Meeting abstract, from the 20th Annual Meeting of the American-Society-of-Breast-Surgeons Conference, Dallas, Texas, 30 Apr - 5 May, 2019.

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015) (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Algurafi, H., Alhasso, A., Bliss, P., Bloomfield, D., Emson, M., Goodman, A., Harnett, A., Passant, H., Tsang, Y., Wheatley, D., Bliss, J., & Yarnold, J. (2018). FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology - Biology - Physics, 102(5), 1603 -1604. https://doi.org/10.1016/j.ijrobp.2018.08.049

Conference abstract.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial (2018)
Journal Article
Velikova, G., Jane Williams, L., Willis, S., Michael Dixon, J., Loncaster, J., Hatton, M., Clarke, J., Kunkler, P. I. H., H Kunkler, I., S Russell, N., trial UK investigators, M. S., Alhasso, A., Adamson, D., Algurafi, H., Allerton, R., Anandadas, C., Bahl, A., Barraclough, L., Barrett-Lee, P., Barthakur, U., …Yuille, F. (2018). Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, 19(11), 1516 - 1529. https://doi.org/10.1016/s1470-2045%2818%2930515-1

Background
Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radio... Read More about Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018)
Journal Article
Corrie, P., Marshall, A., Nathan, P., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C., Marples, M., Danson, S., Marshall, E., Houston, S., Board, R., Waterston, A., Nobes, J., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., …Coltart, R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 29(8), 1843 -1852. https://doi.org/10.1093/annonc/mdy229

Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recur... Read More about Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. (2018)
Journal Article
Winters, Z. E., Horsnell, J., Elvers, K. T., Maxwell, A. J., Jones, L. J., Shaaban, A. M., Schmid, P., Williams, N. R., Beswick, A., Greenwood, R., Ingram, J. C., Saunders, C., Vaidya, J. S., Esserman, L., Jatoi, I., & Brunt, A. M. (2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 2(4), 162 - 174. https://doi.org/10.1002/bjs5.53

Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC) breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is uncertain. Inconsistencies relate to definitions, in... Read More about Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers..

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. (2017)
Journal Article
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., Bhattacharya, I. S., Brunt, A. M., Ciurlionis, L., Chan, C., Donovan, E. M., Emson, M. A., Harnett, A. N., Haviland, J. S., Hopwood, P., Jefford, M. L., Kaggwa, R., Sawyer, E. J., Syndikus, I., Tsang, Y. M., …Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048 - 1060. https://doi.org/10.1016/S0140-6736%2817%2931145-5

BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy r... Read More about Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial..

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial (2017)
Journal Article
Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., Agrawal, R., Banerji, J., Bertelli, G., Bloomfield, D., Brunt, A. M., Helena Earl, P., Paul Ellis, P., Gaunt, C., Gillman, A., Hearfield, N., Laing, R., Murray, N., Couper, N., Stein, R. C., …Bliss, J. M. (2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, 18(7), 929 - 945. https://doi.org/10.1016/S1470-2045%2817%2930404-7

Background
Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial (2016)
Journal Article
Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., Coles, C., Goodman, A., Bahl, A., Churn, M., Zotova, R., Sydenham, M., Griffin, C. L., Morden, J. P., & Bliss, J. M. (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-118. https://doi.org/10.1016/j.radonc.2016.02.027

BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undert... Read More about Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.